

Investment ideas. Stocks.

Progress So ware Corpora on (PRGS US) develops, markets, and distributes so ware. It serves customers in the United States. The Company specializes in so ware for crea on and deployment of applica ons and off rs databases, applica on, messaging servers, and development tools. The most important product is OPenEdge pla orm which allows users to create applica ons.

Company	PROGRESS SOFTWARE		
Ticker	PRGS US		
Sector	So ware development		
Capitalization, \$ million	1,869		
EV, \$ million	2,180		
Dividend yield	1.6%		
Entry level, \$	40.55		
Current price, \$	42.27		
Result	4.2%		

Source: Bloomberg

Key investment a rac veness factors.

- 1) **Growing demand for life insurance.** According to MIB Group, the number of applications for life insurance policies spiked 4% in 2020. This has been a record year-on-year growth figure in this segment since 2001. The increase in the number of applications was catalyzed by nagging concern about COVID-19 death rates extensively spread by media. Interestingly, the growth was mainly driven by younger people: the number of applications from persons under 45 increased by 7.9% (and by only 3.8% from people aged 45 59). We won't rule out possibility this trend will remain in the future, which will undoubtedly have a positive effect on Lincoln National's performance.
- 2) Finance: high pro tability and dividends, and low debt. According to forecasts, the company is expected to show revenue growth at 1.5% due to the increase in demand for insurance in 2020. On the other hand, net profit may decrease due to growing insurance payouts. At the same time, Bloomberg expects profit figures to return to growth in 2021. Apart from that, there are benefits such as high operating margin (about 34%), good dividends (yield at 3.4%) and low debt burden (net debt to operating margin at 0.6x).
- 3) **Substan al discount with reference to mul pliers.** Lincoln National's stock is traded momentarily substantially cheaper than U.S. benchmarks in insurance companies sector. Discount for P/S multiplier is around 97%, for P/Book Value 345%, and for P/E 119%.

Key risks. In theory, growing COVID-19 death rates can do the company more harm than good, because in this case insurance premiums will grown as well, which will put pressure on net profit. Low rates are a risk too, since companies invest the major portion of insurance premiums in high-rated bonds. Additionally, competition is very tight today in the U.S. insurance and finance consulting sector.





Financial highlights, \$ million	2019	2020P*	2021P*	Change, %
Revenue	413	442	516	17%
Gross profit	338	380	455	20%
EBITDA	148	179	196	9%
Net profit	66	102	147	43%
EPS	1.48	2.28	3.25	43%
Gross margin	82%	77%	79%	2%
EBITDA margin	36%	41%	38%	-3%
Net margin	16%	23%	28%	5%
Debt burden, \$ million	2019	2020	2021P*	Change, %
Gross debt	295	416	417	0%
Cash	174	106	106	0%
Net debt	121	310	311	0%
Net debt/EBITDA	0.1	2.1	1.7	-
Benchmarking against similar companies	Country	P/S	EV/EBITDA	P/E
GAZPROM	Russia	0.7	5.0	5.6
NOVATEK	Russia	4.6	12.8	15.0
TEEKAY	USA	1.9	7.1	4.3
DHT HOLDINGS	USA	3.0	6.1	13.6
DORIAN	USA	2.0	5.5	6.3
HAFNIA	Norway	1.2	7.7	10.3
NAVIGATOR	USA	1.6	6.6	7.2
INTERNATIONAL SEWAYS	USA	1.5	7.3	12.4
Weighted average		2.1	7.3	9.4
PROGRESS SOFTWARE	USA	3.6	11.1	12.8
Discount/(premium)		-43%	-35%	-27%

*P – Projection

Source: Bloomberg

Moscow Partners Equity Research





Global Markets Research Department

Moscow Partners 123056 Moscow 23 Maly Tishinsky lane, building 1

Tel.: +7 495 787-52-56 Fax: +7 495 787-52-57

www.moscowpartners.com

DISCLAIMER OF LIABILITY

This review is provided for informational purposes. It does not constitute, in whole or in any part, an offer to purchase, sell or conduct any transactions or investments in relation to the securities specified in the review. It is not a recommendation for making any investment decisions. The information used in this review is obtained from supposedly reliable sources, however, no verification of this information has been carried out, and Moscow Partners does not give any guarantees of the correctness of the information in this review. Moscow Partners is not obliged to change or update this review in any way, but the company has the right to change and/or update this review, at its sole discretion and without any notice. This review may not be reproduced, published or distributed in whole or in any part, links on it or quotations from it may not be made without a prior written permission of Moscow Partners. Moscow Partners is not responsible for any adverse consequences, including losses (direct or indirect), caused as a result of using the information contained in this review, or as a result of investment decisions made on the basis of this information.